Loading events...
Elixir Medical’s DynamX bioadaptor has been shown to diminish target lesion failure (TLF) by 48% in a landmark clinical trial. Elixir Medical’s coronary implant, DynamX bioadaptor, has been proven to significantly reduce the risk of device-related cardiac events compared with current-generation drug-eluting stents in a landmark clinical trial in coronary artery disease (CAD).
Monday, October 27, 2025
San Francisco, USA
Are you the organizer?
Claim this event to edit details, see analytics, and get leads
Elixir Medical’s DynamX bioadaptor has been shown to diminish target lesion failure (TLF) by 48% in a landmark clinical trial. Elixir Medical’s coronary implant, DynamX bioadaptor, has been proven to significantly reduce the risk of device-related cardiac events compared with current-generation drug-eluting stents in a landmark clinical trial in coronary artery disease (CAD).
Receive curated event recommendations based on your interests.
See how WebMobi helps you manage registration, check-in, and analytics.
Request a DemoOr start free trial →TCT 2025: Elixir Medical’s arterial implant drops coronary events by nearly 50% takes place on Monday, October 27, 2025 in San Francisco. All times are in UTC.
WebMobi provides event registration, ticketing, mobile apps, check-in, and analytics — all with zero platform fees.
Get curated B2B events, AI-powered insights, and industry trends delivered to your inbox